Q: Is 360 High-Risk Vulnerability Immunization Tool V2.0 a good alternative to ZAST.AI?

360 High-Risk Vulnerability Immunization Tool V2.0 and ZAST.AI serve similar Vulnerability Assessment use cases: both are Vulnerability Assessment tools, both cover Zero Day, CVE. Review the feature comparison above to determine which fits your requirements.

Question 1

What is the difference between 360 High-Risk Vulnerability Immunization Tool V2.0 vs ZAST.AI?

Accepted Answer

**360 High-Risk Vulnerability Immunization Tool V2.0**: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). headquartered in China. Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

**ZAST.AI**: AI agent that finds, exploits & verifies zero-day vulns with zero false positives. built by ZAST.AI. Core capabilities include AI-driven source code logic analysis, Automated vulnerability identification, Proof-of-concept (POC) exploit generation..

Both serve the Vulnerability Assessment market but differ in approach, feature depth, and target audience.

Question 2

What features do 360 High-Risk Vulnerability Immunization Tool V2.0 vs ZAST.AI offer?

Accepted Answer

**360 High-Risk Vulnerability Immunization Tool V2.0** differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. **ZAST.AI** differentiates with AI-driven source code logic analysis, Automated vulnerability identification, Proof-of-concept (POC) exploit generation.

Question 3

Who makes 360 High-Risk Vulnerability Immunization Tool V2.0 vs ZAST.AI?

Accepted Answer

**360 High-Risk Vulnerability Immunization Tool V2.0** is developed by 360 Security Group (Qihoo 360). **ZAST.AI** is developed by ZAST.AI. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.